Abstract: Patients with lupus nephritis (LN) often require long⁃term treatment with glucocorticoids and/or immunosuppressants.Despite its efficacy in controlling lupus nephritis and preventing renal relapse,prolonged immunosuppressive therapy is associated with unavoidable drug⁃related adverse events.Therefore,there is ongoing clinical exploration into safe withdrawal of immunosuppressive therapy after clinical remission.Recent studies have confirmed that it is feasible to safely taper off glucocorticoids or immunosuppressants in low⁃risk patients under close surveillance,with multidimensional assessment of relapse risk based on baseline risk factors,duration of sustained remission,and depth of remission.In contrast,high⁃risk patients should receive long⁃term maintenance therapy at the lowest effective dose.This review focuses on clinical research and decision⁃making regarding the withdrawal of immunosuppressive therapy in LN patients.